Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

被引：0
作者：
P. Neven
P. A. Fasching
S. Chia
G. Jerusalem
M. De Laurentiis
S.-A. Im
K. Petrakova
G. V. Bianchi
M. Martín
A. Nusch
G. S. Sonke
L. De la Cruz-Merino
J. T. Beck
J. P. Zarate
Y. Wang
A. Chakravartty
C. Wang
D. J. Slamon
机构：
[1] Universitair Ziekenhuis Leuven,Multidisciplinary Breast Centre
[2] University Hospital Erlangen,Cancer Research Institute, Seoul National University Hospital
[3] Friedrich-Alexander University Erlangen-Nuremberg,Fondazione Istituto di Ricovero e Cura a Carattere Scientifico
[4] British Columbia Cancer Agency,Instituto de Investigación Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama
[5] CHU Liege and Liège University,undefined
[6] Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”,undefined
[7] Seoul National University College of Medicine,undefined
[8] Masaryk Memorial Cancer Institute,undefined
[9] Istituto Nazionale dei Tumori,undefined
[10] Universidad Complutense,undefined
[11] Practice for Hematology and Internal Oncology,undefined
[12] Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center,undefined
[13] Hospital Universitario Virgen Macarena,undefined
[14] Highlands Oncology,undefined
[15] Novartis Pharmaceuticals Corporation,undefined
[16] Novartis Pharma AG,undefined
[17] David Geffen School of Medicine at UCLA,undefined
来源：
Breast Cancer Research | / 25卷
关键词：
Ribociclib; CDK4/6 inhibitor; Advanced breast cancer; Overall survival; First line;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 75 条
[21]  
Chia S(2021)Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the Penelope-B trial J Clin Oncol 39 1518-undefined
[22]  
Finn R(2023)Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: primary results from the Phase III NATALEE trial J Clin Oncol 41 LBA500-undefined
[23]  
Rugo H(2023)Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial Lancet Oncol 24 77-undefined
[24]  
Dieras VC(2021)Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study Ann Oncol 32 1571-undefined
[25]  
Goetz M(2020)Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE) J Clin Oncol 38 3987-undefined
[26]  
Toi M(undefined)undefined undefined undefined undefined-undefined
[27]  
Huober J(undefined)undefined undefined undefined undefined-undefined
[28]  
Turner NC(undefined)undefined undefined undefined undefined-undefined
[29]  
Slamon DJ(undefined)undefined undefined undefined undefined-undefined
[30]  
Ro J(undefined)undefined undefined undefined undefined-undefined
12345678